Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-087 manufacturers

Filters

1 products found

pp-087

Tablets

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA, China
Unavailable markets
China
Registered in
China
Comments
Indication: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) requiring systemic treatment after prior therapy including BTK inhibitors; additional development ongoing in multiple hematologic malignancies and select solid tumors. Clinical stage: China conditional approval (2025) for treated CLL/SLL; global Phase Ib/II and four Phase III trials in CLL/SLL, AML, MDS. Modality: Small-molecule. Mechanism: Highly selective inhibitor of BCL-2 that restores apoptotic signaling in malignant cells; designed with a short elimination half-life and high Cmax to achieve potent “hit-and-run” target engagement while potentially reducing systemic toxicities. Route: Oral. Differentiation: First China-approved BCL-2 inhibitor; rapid 1-week ramp-up with lower toxicity potential.
Manufacturer #38620

A global, clinical-stage biopharmaceutical company discovering, developing and commercializing small-molecule therapies addressing unmet needs in hematological cancers and other serious diseases. It advances programs through international registrational trials with strategic development and partnership goals. The organization integrates R&D and global expansion efforts.
 

 

 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.